Correlation of AS160 phosphorylation with tumor cell proliferative activity in primary breast cancer

doi:10.3969/j.issn.1673-8640.2016.03.016

Abstract

Abstract:

Objective To investigate the correlation of phosphorylation AS160 （Thr642） regulation with tumor cell proliferative activity in breast cancer tissue. Methods The clinical data of 152 patients with breast cancer in 85 Hospital of People's Liberation Army from January 2003 to January 2015 were analyzed retrospectively. Immunohistochemical method was used to determine phosphorylation AS160（Thr642） and proliferation Ki-67（MIB-1） levels. Mitotic index was evaluated,and the expression characteristics of phosphorylation AS160（Thr642） was investigated in breast cancer cell line MDA-MB-231. The correlations of phosphorylation AS160（Thr642） with mitotic index and Ki-67（MIB-1） were analyzed by Spearman nonparametric test. Results The phosphorylation AS160 （Thr642） was positively correlated with mitotic index （r=0.493,P<0.001） and Ki-67 （MIB-1）（r=0.472,P<0.001）. The phosphorylation AS160（Thr642） in mitotic tumor cells was strongly positive in cell line and breast cancer tissue. Conclusions The phosphorylation AS160 is correlated with tumor cell proliferative activity and might be useful as a marker and a potential treatment target for breast cancer.

Key words: AS160, Breast cancer, Phosphorylation, Cell proliferation

CLC Number:

R446.62

JIANG Xiaohua, WEI Yu, SUN Jianwen, REN Konghua, CUI Beinian, WANG Wei, CHENG Yi. Correlation of AS160 phosphorylation with tumor cell proliferative activity in primary breast cancer[J]. Laboratory Medicine, 2016, 31(3): 220-223.

Figures/Tables 5

References 12

1	BERTUCCI F,FINETTI P,ROCHE H,et al.Comparison of the prognostic value of genomic grade index,Ki67 expression and mitotic activity index in early node-positive breast cancer patients[J]. Ann Oncol,2013,24(3):625-632.
2	苏静,郑杰. 肿瘤增殖标记分子Ki-67和增殖细胞核抗原及其在病理诊断中的应用[J]. 中华病理学杂志,2009,38(8):568-571.
3	NILSSON C,KOLIADI A,JOHANSSON I,et al.High proliferation is associated with inferior outcome in male breast cancer patients[J].Mod Pathol,2013,26(1):87-94.
4	JIANG XH,SUN JW,XU M,et al.Frequent hyperphosphorylation of AS160 in breast cancer[J]. Cancer Biol Ther,2010,10(4):362-367.
5	姜小华,李君,孙建文,等.原发性乳腺癌p-AS160(Thr642)水平与常用临床病理指标的相关性研究[J]. 中华乳腺病杂志:电子版,2012,6(3):298-303.
6	TAVASSOLI FA,DEVILEE P.World Health Organization classification of tumours.Pathology and genetics of tumours of the breast and female genital organs[M]. Lyon:IARC Press,2003:10.
7	JALAVA P,KUOPIO T,JUNTTI-PATINEN L,et al.Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index[J]. Histopathology,2006,48(6):674-682.
8	SAKAMOTO K,HOLMAN GD.Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic[J]. Am J Physiol Endocrinol Metab,2008,295(1): E29-E37.
9	LIU J,ZHANG JF,LU JZ,et al.Astragalus polysaccharide stimulates glucose uptake in L6 myotubes through AMPK activation and AS160/TBC1D4 phosphorylation[J].Acta Pharmacol Sin, 2013,34(1): 137-145.
10	BARTLETT JM.Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies:current status and future directions[J]. Clin Breast Cancer,2010,10(Suppl 3):S86-S95.
11	SALH B,MAROTTA A,WAGEY R,et al.Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer[J]. Int J Cancer,2002,98(1):148-154.
12	GULLICK WJ,SRINIVASAN R.The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer[J]. Breast Cancer Res Treat,1998,52(1-3):43-53.

[1]	WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817.
[2]	CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578.
[3]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429.
[4]	LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239.
[5]	LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147.
[6]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[7]	SHANG Zhenjun, WEI Wei, LIU Ruihan. Effect of inhibiting PTBP1 on the proliferation and invasiveness of choroidal melanoma cells [J]. Laboratory Medicine, 2023, 38(1): 51-55.
[8]	WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis [J]. Laboratory Medicine, 2022, 37(9): 815-820.
[9]	YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517.
[10]	YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348.
[11]	LI Mingwu, WANG Qinzhi, SUN Farui. Influence of MUC16 on the cell proliferation and invasion of osteosarcoma cells [J]. Laboratory Medicine, 2022, 37(10): 979-983.
[12]	ZHANG Xinyue, CHEN Liang, ZHENG Yu. Correlation between serum C peptide and insulin-like growth factor binding protein 3 and the risk of breast cancer patient death [J]. Laboratory Medicine, 2022, 37(1): 36-40.
[13]	LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718.
[14]	YUAN Muge, WU Wenjian, HU Zhaohui, CHEN Jiachang, YU Shihui, OU Xiaohua, MAO Linlin, WU Haiyan. Germline mutation detection in early-stage breast cancer by next-generation sequencing [J]. Laboratory Medicine, 2021, 36(3): 325-329.
[15]	LIU Xiufen, AO Hongfeng, AO Jinping. Expression of programmed cell death 5 in breast cancer and its clinical value [J]. Laboratory Medicine, 2021, 36(11): 1151-1158.